WO2018009906A1 - Conjugués cellules entières – protéines, et procédés de fabrication de ces derniers - Google Patents

Conjugués cellules entières – protéines, et procédés de fabrication de ces derniers Download PDF

Info

Publication number
WO2018009906A1
WO2018009906A1 PCT/US2017/041258 US2017041258W WO2018009906A1 WO 2018009906 A1 WO2018009906 A1 WO 2018009906A1 US 2017041258 W US2017041258 W US 2017041258W WO 2018009906 A1 WO2018009906 A1 WO 2018009906A1
Authority
WO
WIPO (PCT)
Prior art keywords
whole cell
protein
antigen
immunogenic
polyol
Prior art date
Application number
PCT/US2017/041258
Other languages
English (en)
Inventor
John J. Mekalanos
Jeremy Andrew IWASHKIW
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Publication of WO2018009906A1 publication Critical patent/WO2018009906A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to immunogenic whole cell-protein conjugates, pharmaceutical
  • compositions containing immunogenic whole cell-protein conjugates methods of making immunogenic whole cell-protein conjugates, methods of making immunogenic polysaccharide-protein conjugates via immunogenic whole cell-protein conjugates, and methods of generating an immune response in a subject using immunogenic whole cell-protein conjugates.
  • Capsules are exterior surface components of microbes that are typically composed of polymers of organic compounds such as carbohydrates, amino acids, or alcohols. Capsules are quite diverse chemically. The monomeric units that make up capsules (e.g., carbohydrates) can be linked together in various molecular configurations and can be further substituted with phosphate, nitrogen, sulfate, and other chemical modifications. These chemical variations allow capsules to present numerous antigenic targets on the microbial exterior surface, thus allowing escape from the host immune response directed at these targets.
  • Capsules can also be virulence factors which prevent microbes from being phagocytosed and killed by host leukocytes.
  • Antibodies against capsules provide a potent defense against encapsulated organisms by fixing complement to the microbial exterior surface, which can result in their lysis or their opsonization, uptake, and killing by phagocytic host immune cells.
  • the most potent antibodies against capsules are IgG antibodies.
  • Capsules that fail to induce significant levels of IgG are called T-independent antigens. Covalent coupling of a protein to T-independent antigens such as capsules renders them "T-dependent” and such "conjugates" can elicit an IgG response.
  • immunogenic conjugates directed to capsules and other T-independent antigens that do not evoke strong immune responses or IgG antibodies.
  • immunogenic conjugates are needed to protect against various infectious diseases such as infection by anthrax, pneumococcus, influenzae Type B, meningococcus, streptococcus, mycobacteria, Candida, malaria, and other bacterial, fungal and protozoan pathogens.
  • the invention relates to immunogenic whole cell-protein conjugates containing immunogenic whole cell-protein conjugate containing a carrier protein and a whole cell having an exterior surface including a polyol antigen that is linked to the carrier protein through a linker.
  • the linker can be covalent, or the linker may include an affinity pair.
  • the invention also provides methods of making such immunogenic conjugates using whole cells, methods of making polyol antigen-protein conjugates using whole cells, and methods of generating an immune response in a subject using the immunogenic conjugates.
  • the linker in the whole cell-protein conjugates of the invention is formed by a reaction between a cyanate group bonded to the polyol antigen and a hydrazine-activated carrier protein.
  • the linker can be represented by a formula:
  • Z 1 is a bond to an oxygen atom in the polyol antigen
  • Z 2 is a bond to a carbonyl group in the carrier protein
  • Z 3 is O or NH
  • each of n and m is 0 or 1 , and
  • L when present, is C2-6 alkanediyl or Ce- ⁇ arenediyl.
  • the carrier protein is a diphtheria toxin, diphtheria toxoid, tetanus toxin, tetanus toxoid, Pseudomonas aeruginosa exotoxin A, cholera toxin B subunit, tetanus toxin fragment C, bacterial flagellin, pneumolysin, an outer membrane protein of Neisseria menningitidis, Pseudomonas aeruginosa Hcp1 protein, Escherichia coli heat labile enterotoxin, shiga-like toxin, human LTB protein, pneumolysin, listeriolysin O, a protein extract from whole bacterial cells, the dominant negative mutant (DNI) of the protective antigen of Bacillus anthracis, or Escherichia coli beta-galactosidase.
  • DNI dominant negative mutant
  • the whole cell is a Pseudomonas aeruginosa or Streptococcal cell (e.g., a Streptococcus pneumonia cell (e.g., Streptococcus pneumonia type 4).
  • a Streptococcus pneumonia cell e.g., Streptococcus pneumonia type 4
  • the whole cell is a Streptococcus pneumonia type 1 , 2, 3, 4, 5, 6A, 6B, 7A, 7B, 7C, 7F, 8, 9A, 9L, 9N, 9V, 10A, 10B, 10F, 1 1 A, 1 1 B, 1 1 C, 1 1 D, 1 1 F, 12A, 12B, 12F, 13, 14, 15A, 15B, 15C, 15F, 1 6A, 16F, 17A, 17F, 1 8A, 18B, 18C, 18F, 19A, 19B, 1 9C, 19F, 20, 21 , 22F, 23B, 23F, 24A, 24B, 24F, 25A, 25F, 27, 28A, 28F, 29, 31 , 32A, 32F, 33A, 33B, 33D, 33F, 34, 35A, 35B, 35F, 36, 37, 38, 39, 40, 41 A, 41 F, 42, 43, 44, 45, 46, 47A, 47F, or 48.
  • the bacterial flagellin is the Vibrio cholerae flagellin protein.
  • the shiga-like toxin is the Shigella SltB2 protein.
  • the carrier protein molecules are pneumolysin.
  • the carrier protein is listeriolysin O.
  • the carrier protein is diphtheria toxin.
  • the carrier protein is diphtheria toxoid. In further embodiments, the carrier protein is tetanus toxin. In yet further embodiments, the carrier protein is tetanus toxoid.
  • the polyol antigen is a polysaccharide antigen. In yet other embodiments, the polyol antigen comprises at least 18 carbohydrate residues. In still other embodiments, the polyol antigen comprises a Streptococcus pneumoniae polysaccharide, Francisella tularensis polysaccharide, Bacillus anthracis polysaccharide, Haemophilus influenzae polysaccharide, Salmonella typhi
  • the Streptococcus pneumoniae polysaccharide is capsular type 1 , 2, 3, 4, 5, 6A, 6B, 7A, 7B, 7C, 7F, 8, 9A, 9L, 9N, 9V, 10A, 10B, 10F, 1 1 A, 1 1 B, 1 C, 1 1 D, 1 1 F, 12A, 12B, 12F, 13, 14, 15A, 15B, 15C, 15F, 16A, 16F, 17A, 17F, 1 8A, 18B, 18C, 18F, 19A, 19B, 1 9C, 19F, 20, 21 , 22F, 23B, 23F, 24A, 24B, 24F, 25A, 25F, 27, 28A, 28F, 29, 31 , 32A, 32F, 33A, 33B, 33D, 33F, 34, 35A, 35B
  • the Francisella tularensis polysaccharide is O antigen.
  • the polyol antigen is a microbial capsular polymer.
  • the whole cell is a heat inactivated whole cell pathogen or a chemically inactivated whole cell pathogen, or is chemically inactivated with formaldehyde or glutaraldehyde.
  • the immunogenic whole cell-protein conjugate when administered to a mammal, elicits a T-cell dependent immune response in the mammal.
  • the molar ratio of the polyol antigen to the carrier protein in the immunogenic whole cell- protein conjugate is 1 to 1 .
  • the invention provides a pharmaceutical composition containing the immunogenic whole cell-protein conjugate of the invention and a pharmaceutically acceptable carrier or excipient.
  • the pharmaceutical composition does not comprise an adjuvant.
  • the invention provides a method of preparing an immunogenic conjugate (e.g., the immunogenic whole cell-protein conjugate of the invention) by contacting a hydrazine-activated carrier protein with a whole cell having an exterior surface including a polyol antigen bonded to at least one cyanate.
  • the method is for preparing a polyol antigen-carrier protein conjugate by contacting a hydrazine-activated carrier protein with a whole cell having an exterior surface including a polyol antigen bonded to at least one cyanate, and, after the contacting, lysing the whole cell to produce the polyol antigen-carrier protein conjugate.
  • the method further includes purifying the polyol antigen-carrier protein conjugate away from unconjugated cellular components.
  • the method further includes preparing the hydrazine-activated carrier protein by contacting a carrier protein with a hydrazine source agent.
  • the method further includes preparing the whole cell having an exterior surface including a polyol antigen bonded to at least one cyanate by contacting an electrophilic source of cyanide with a whole cell including a polyol antigen.
  • the electrophilic source of cyanide is CDAP or cyanogen bromide.
  • the invention provides a method of generating an immune response in a subject comprising administering the pharmaceutical composition of the invention to the subject, where the immunogenic whole cell-protein conjugate elicits a T-cell dependent immune response in the subject.
  • the subject is an infant, a child, or an adolescent.
  • the pharmaceutical composition is administered to the subject parenterally.
  • the pharmaceutical composition is administered to the subject enterally (e.g., orally or through a rectal suppository), or nasally (e.g., through inhalation or nasal spray)).
  • Z 4 is a bond to a polyol antigen
  • Z 5 is a bond the carrier protein
  • each of n, m, and k is independently 0 or 1 , and
  • L when present, is C2-6 alkanediyl or Ce- ⁇ arenediyl.
  • the invention provides an immunogenic whole cell-protein conjugate comprising a carrier protein and a whole cell having an exterior surface comprising a polyol antigen, wherein said polyol antigen is covalently linked to said carrier protein through a linker Z 1 -C(0)-N(H)- (N(H))k-L-N(H)-C(0)-CH 2 -S-L 1 -C(0)-Z 2 ,
  • Z 1 is a bond to an oxygen atom in the polyol antigen
  • Z 2 is a bond to an amino group in the carrier protein
  • k 0 or 1
  • L is C2-6 alkanediyl
  • L 1 is C2-6 alkanediyl optionally substituted with a protected amino group.
  • Z 4 is a bond to a polyol antigen
  • Z 5 is a bond the carrier protein
  • L is C2-6 alkanediyl or Ce- ⁇ arenediyl.
  • the invention provides an immunogenic whole cell-protein conjugate comprising a carrier protein and a whole cell having an exterior surface comprising a polyol antigen, wherein said polyol antigen is covalently linked to said carrier protein through a linker of formula:
  • Z 1 is a bond to an oxygen atom in the polyol antigen
  • Z 2 is a bond to an amino group in the carrier protein
  • each L is independently C2-6 alkanediyl, and L 1 is C2-6 alkanediyl.
  • the invention provides an immunogenic whole cell-protein conjugate comprising a carrier protein and a whole cell having an exterior surface comprising a polyol antigen, wherein said polyol antigen is covalently linked to said carrier protein through a linker Z 1 -C(0)-N(H)-Z 5 , wherein Z 1 is a bond to an oxygen atom in the polyol antigen, and Z 2 is a bond to a carrier protein.
  • the invention provides an immunogenic whole cell-protein conjugate comprising a carrier protein and a whole cell having an exterior surface comprising a polyol antigen, wherein said polyol antigen is covalently linked to said carrier protein through a linker
  • Z 1 is a bond to an oxygen atom in the polyol antigen
  • Z 2 is a bond to an amino group in the carrier protein
  • each of L and L 1 is independently C2-6 alkanediyl.
  • the invention provides an immunogenic whole cell-protein conjugate comprising a carrier protein and a whole cell having an exterior surface comprising a polyol antigen, wherein said polyol antigen is linked to said carrier protein through a linker comprising an affinity pair.
  • the linker including an affinity pair is of formula:
  • Z 2 is a bond to a carrier protein
  • Z 3 is O or NH
  • L is C2-10 alkanediyl or -[-CH2-CH2-(-0-CH2-CH2-)n]-, where n is an integer from 0 to 24, L 1 is -N(H)- or -N(H)-N(H)-,
  • L 2 is -N(H)-, -C(O)-, -C(0)-N(H)-, or -N(H)-C(0)-,
  • AP is a complementary affinity pair.
  • the complementary affinity pair is a biotin/streptavidin, biotin/avidin, or biotin/neutravidin pair.
  • the carrier protein is a diphtheria toxin, diphtheria toxoid, tetanus toxin , tetanus toxoid, Pseudomonas aeruginosa exotoxin A, cholera toxin B subunit, tetanus toxin fragment C, bacterial flagellin, pneumolysin, an outer membrane protein of Neisseria menningitidis, Pseudomonas aeruginosa Hcp1 protein, Escherichia coli heat labile enterotoxin, shiga-like toxin, human LTB protein, pneumolysin, listeriolysin O, a protein extract from whole bacterial cells, a mutant form of these proteins that ablates toxicity, e.g., the dominant negative mutant (DNI) of the protective antigen of Bacillus anthracis, or a microbial cytoplasmic protein, e.g.
  • DNI
  • the whole cell is a Pseudomonas aeruginosa or Streptococcal cell.
  • the whole cell is a Streptococcus pneumonia cell.
  • the whole cell is a Streptococcus pneumonia type 1 , 2, 3, 4, 5, 6A, 6B, 7A, 7B, 7C, 7F, 8, 9A, 9L, 9N, 9V, 10A, 10B, 10F, 1 1 A, 1 1 B, 1 1 C, 1 1 D, 1 1 F, 12A, 12B, 12F, 13, 14, 15A, 15B, 15C, 15F, 1 6A, 16F, 17A, 17F, 1 8A, 18B, 18C, 18F, 19A, 19B, 1 9C, 19F, 20, 21 , 22F, 23B, 23F, 24A, 24B, 24F, 25A, 25F, 27, 28A, 28F, 29, 31 , 32A, 32F, 33A, 33B,
  • the bacterial flagellin is the Vibrio cholerae flagellin protein.
  • the shiga-like toxin is the Shigella SltB2 protein.
  • the carrier protein molecules are pneumolysin.
  • the carrier protein is listeriolysin O.
  • the carrier protein is diphtheria toxin.
  • the carrier protein is diphtheria toxoid.
  • the carrier protein is tetanus toxin.
  • the carrier protein is tetanus toxoid.
  • the polyol antigen is a polysaccharide antigen.
  • the polyol antigen comprises at least 18 carbohydrate residues.
  • the polyol antigen comprises a Streptococcus pneumoniae polysaccharide,
  • Francisella tularensis polysaccharide Bacillus anthracis polysaccharide, Haemophilus influenzae polysaccharide, Salmonella typhi polysaccharide, Salmonella species polysaccharide, Shigella polysaccharide, or Neisseria meningitidis polysaccharide.
  • the Streptococcus pneumoniae polysaccharide is capsular type 1 , 2, 3, 4, 5, 6A, 6B, 7A, 7B, 7C, 7F, 8, 9A, 9L, 9N, 9V, 1 0A, 10B, 10F, 1 1 A, 1 1 B, 1 1 C, 1 1 D, 1 1 F, 12A, 12B, 12F, 13, 14, 15A, 1 5B, 15C, 15F, 1 6A, 16F, 17A, 17F, 18A, 18B, 18C, 18F, 19A, 19B, 19C, 19F, 20, 21 , 22F, 23B, 23F, 24A, 24B, 24F, 25A, 25F, 27, 28A, 28F, 29, 31 , 32A, 32F, 33A, 33B, 33D, 33F, 34, 35A, 35B, 35F, 36, 37, 38, 39, 40, 41 A, 41 F, 42, 43, 44, 45,
  • the Francisella tularensis polysaccharide is O antigen.
  • the polyol antigen is a microbial capsular polymer.
  • the whole cell is a heat inactivated whole cell pathogen.
  • the whole cell is a chemically inactivated whole cell pathogen.
  • the immunogenic whole cell-protein conjugate when administered to a mammal, elicits a T-cell dependent immune response in said mammal.
  • the whole cell is a bacterial cell.
  • the whole cell is a fungal cell.
  • the fungal cell is Candida.
  • the invention provides a pharmaceutical composition comprising the immunogenic whole cell-protein conjugate of the invention and a pharmaceutically acceptable carrier or excipient.
  • administering is meant providing to a subject an immunogenic conjugate in a dose sufficient to induce an immune response in the subject, where the immune response results in the production of antibodies that specifically bind an antigen contained in the immunogenic conjugate.
  • Administering desirably includes parenteral administration (e.g., by subcutaneous, intramuscular, intravenous, or intradermal injection). While administering by a means that physically penetrates the dermal layer is desirable (e.g., a needle, airgun, or abrasion), the immunogenic conjugates of the invention can also be administered by transdermal absorption. Desirably, administration involves the inclusion of the appropriate immune adjuvants.
  • Administering also includes enterally (for instance, by oral administration) by ingestion of an immunogenic conjugate in the form of e.g., a liquid, powder, capsule, or tablet.
  • Administering may involve a single administration of an immunogenic conjugate or administering an immunogenic conjugate in multiple doses.
  • a second administration is designed to boost production of antibodies in a subject to reduce the likelihood of infection by an infectious agent.
  • the frequency and quantity of the dosage of immunogenic conjugate depends on the specific activity of the immunogenic conjugate and can be readily determined by routine experimentation.
  • alkanediyl is meant a divalent, saturated hydrocarbon group having a total of 2 to 6 carbon atoms.
  • An alkanediyl may be linear or branched.
  • Non-limiting examples of the alkanediyl groups are: ethane-1 ,2-diyl; propane-1 ,3-diyl; propane-1 ,2-diyl ; 2-methyl-propane-1 ,3-diyl ; butane-1 ,2-diyl; butane- 1 ,3-diyl ; and butane-1 ,4-diyl.
  • affinity pair is meant a non-covalent complex of two complementary moieties.
  • the non-covalent complex has a dissociation constant of 10 13 M or less at ca. 25 °C in water.
  • Affinity pairs are known in the art.
  • affinity pairs may include lectins/sugar structures, microbial toxins/receptors, antibodies/haptens, avidins/biotins or mimics, adhesins/receptors, maltose binding protein/maltose, and maltose binding protein/maltotriose.
  • lectin/sugar affinity pairs include concanavalin A/manose and concavalin A/glucose.
  • Non-limiting examples of microbial toxin/receptor affinity pairs include toxins binding RGD peptide sequence/RGD peptides, heat labile enterotoxin of E. co//7L-galactose, and ricin toxin/galactose.
  • Non-limiting examples of antibodies/haptens include antibodies/trinitrobenzene.
  • Non-limiting examples of avidin/biotin affinity pairs include biotin/streptavidin, biotin/avidin, and biotin/neutravidin pairs.
  • Non-limiting examples of avidin/biotin peptide mimics are known in the art (see, e.g., Dudak et al., Molecules, 16:774-789, 201 1 ).
  • Non-limiting examples of adhesin/receptor affinity pairs include Type I fimbriae (e.g., FimH) binding mannose residues.
  • arenediyl is meant a divalent, cyclic, aromatic group having a total of 6 to 10 carbon atoms.
  • Non-limiting examples of the arenediyl groups are phenylene and napthylene.
  • amino acid is meant a residue in a polypeptide sequence that can be naturally occurring or synthetic.
  • a naturally occurring amino acid is one encoded by the genetic code.
  • a synthetic amino acid is one that is analogous in chemical structure to a naturally occurring amino acid; or one that has a different chemical structure from a naturally occurring amino acid yet functions similarly to a naturally occurring amino acid.
  • Amino acids may be referred to herein by their single or three letter abbreviations.
  • antigen as used herein is meant any molecule or combination of molecules that is
  • booster response the activation of memory B-cells that occurs during a second exposure to an antigen, called a “booster response,” and is indicative of a long lived “secondary” memory immune response, resulting in the long lived production of antibodies.
  • carrier protein is meant a protein used in an immunogenic conjugate that invokes an immune response to itself and/or to a polyol antigen covalently linked to a carrier protein.
  • the carrier protein contains an epitope recognized by a T-cell.
  • a carrier protein includes multi-antigenic peptides (MAPs), which are branched peptides and include lysine.
  • MAPs multi-antigenic peptides
  • Exemplary desirable carrier proteins include toxins and toxoids (chemical or genetic), which may be mutant.
  • a carrier protein is diphtheria toxin or a mutant thereof, diphtheria toxoid, tetanus toxin or a mutant thereof, tetanus toxoid, Pseudomonas aeruginosa exotoxin A or a mutant thereof, cholera toxin B subunit, tetanus toxin fragment C, bacterial flagellin, pneumolysin, listeriolysin O (and related molecules), an outer membrane protein of Neisseria menningitidis, Pseudomonas aeruginosa Hcp1 protein,
  • Mutant forms of these proteins can also be carrier proteins, preferably when mutations ablate toxicity or remove epitopes that immunologically cross-react with human proteins.
  • One example of such a protein is the dominant negative mutant (DNI) of the protective antigen of Bacillus anthracis.
  • Pure nontoxic proteins such as Escherichia coli beta-galactosidase and other abundant microbial cytoplasmic proteins can also be carrier proteins.
  • the carrier protein does not contain a sortase protein described in U.S. Serial No. 62/191 ,028.
  • a carrier protein can also include one or more affinity purification tags.
  • Affinity purification tags are known in the art; non-limiting examples of the purification tags are poly-His tags (e.g., oligohistidines having from 5 to 10 His repeating units or from 6 to 9 repeating units), poly-Arg tag, FLAG-tag, calmodulin-tag, S-tag, SBP-tag, TC tag, Strep-tag, VSV-tag (vesicular stomatitis virus tag), Xpress tag, Isopeptag, Halo-tag, GFP-tag, biotin carboxyl carrier protein, chitin binding protein (CBP), maltose binding protein (MBP), glutathione-S-transferase (GST), V5-tag, Myc-tag, and HA-tag.
  • the affinity tags have been described in Terpe Appl. Microbioll. Biotechnol., 60:523-533, 2003; Schmidt et al., Nat. Protocol., 2:1528-1535, 2007; the disclosure of which is
  • conjugated or “conjugation” is meant covalent linking of two or more molecules (e.g., polyol antigen and a protein).
  • covalently linked is meant the presence of a covalent linker bonded to two or more molecules (e.g., a polyol antigen and a carrier protein).
  • DNI is meant the dominant negative mutant (DNI) protein, which is a mutated form of protective antigen (PA) of B. anthracis, as described by Benson et al. (Biochemistry 37:3941 -3948, 1998).
  • electrophilic source of cyanide is meant a compound that upon reaction with a hydroxyl of an alcohol produces a cyanate group.
  • electrophilic sources of cyanide include 1 -cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) or cyanogen bromide.
  • hydrazine-activated carrier protein is meant a carrier protein that is modified to include H2N-NH- group.
  • hydrazine source agent is meant a compound capable of reacting with a carrier protein to produce a hydrazine-activated carrier protein.
  • the formula of a hydrazine source agent is H 2 N-N(H)-(-C(0)-(L-C(0))n-N(H)-N(H)-) m -H, in which each of n and m is 0 or 1 , and L is C2-6 alkanediyl or Ce- ⁇ ⁇ arenediyl.
  • Non-limiting examples of hydrazine source agents are hydrazine and dicarboxylic acid dihydrazides (e.g., succinic acid dihydrazide or adipic acid dihydrazide).
  • infection is meant the invasion of a subject by a microbe, e.g., a bacterium, fungus, parasite, or virus.
  • the infection may include, for example, the excessive multiplication of microbes that are normally present in or on the body of a subject or multiplication of microbes that are not normally present in or on a subject.
  • a subject is suffering from a microbial infection when an excessive amount of a microbial population is present in or on the subject's body or when the presence of a microbial population(s) is damaging the cells or causing pathological symptoms to a tissue of the subject.
  • infectious agent is meant a microbe, e.g., a bacterium, fungus, parasite, or virus that is capable of causing an infection in a subject.
  • immunogenic is meant the capability of a compound to induce an immune response in a subject.
  • the immune response is a T-cell dependent immune response that involves the production of IgG antibodies.
  • microbial capsular polymer is meant a polymer present in or on the capsule coating of a microbe.
  • a microbial capsular polymer is a polyol antigen, e.g., a polysaccharide antigen (e.g., dextrans, alginates, phosphopolysaccharides, polysaccharides with an amino sugar with an N-acetyl substitution, or polysaccharides containing a sulfonylated sugar, or an O side chain of a polysaccharide antigen (e.g., dextrans, alginates, phosphopolysaccharides, polysaccharides with an amino sugar with an N-acetyl substitution, or polysaccharides containing a sulfonylated sugar, or an O side chain of a polysaccharide antigen (e.g., dextrans, alginates, phosphopolysaccharides, polysaccharides with an amino sugar with an N-acety
  • polyalcohol antigen e.g., teichoic acids
  • polyalcohol antigen a polymer having a repeating unit that contains a sugar alcohol.
  • Non-limiting examples of polyalcohols are teichoic acids.
  • polyglycine is meant a (Gly)n sequence. Desirably n is between 2 and 20, or more desirably between 2 and 5, and even more desirably 5 glycine residues.
  • polyol antigen is meant a polyalcohol antigen, a polysaccharide antigen, or a polypeptide antigen having at least one alcohol hydroxyl (e.g., in a side chain, such as in Ser or Thr).
  • polysaccharide antigen is meant a polymer of saccharides (sugars) derived from capsules of encapsulated bacterial pathogens (e.g., Streptococcus pneumoniae, Francisella tularensis, Bacillus anthracis, Haemophilus influenzae, Salmonella typhi, Salmonella species, Shigella, or Neisseria meningitides) that is specifically bound by an antibody or an antibody fragment.
  • saccharides saccharides derived from capsules of encapsulated bacterial pathogens (e.g., Streptococcus pneumoniae, Francisella tularensis, Bacillus anthracis, Haemophilus influenzae, Salmonella typhi, Salmonella species, Shigella, or Neisseria meningitides) that is specifically bound by an antibody or an antibody fragment.
  • protected amino group is meant a group of formula -N(R N1 )2, where each R N1 is
  • N- protecting groups are known in the art. Commonly used /V-protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis,” 3 rd Edition (John Wiley & Sons, New York, 1999), which is incorporated herein by reference.
  • /V-protecting groups include, but are not limited to, amino acids such as alanine, leucine, phenylalanine, and the like; sulfonyl-containing groups such as benzenesulfonyl, p-toluenesulfonyl, and the like; carbamate forming groups such as benzyloxycarbonyl, p- chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2- nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl,
  • CRM phenylthiocarbonyl, and the like, benzyl, triphenylmethyl, benzyloxymethyl, and the like.
  • CRM we mean the nontoxic CRM197 mutant protein of diphtheria toxin.
  • a subject is a mammal such as a human, monkey, dog, cat, mouse, rat, cow, sheep, goat, or horse.
  • the subject is a human, such as a human child.
  • the subject is a human infant, toddler, pre-pubescent child, pubescent child, young adult, or adult under the age of 55 years old.
  • T-cell independent antigen an antigen which results in the generation of antibodies without the cooperation of T lymphocytes.
  • the T-cell independent antigen desirably directly stimulates B lymphocytes without the cooperation of T lymphocytes.
  • exemplary desirable T-cell independent antigens include polysaccharides (e.g., alginic acid (alginate) or dextran) and polyalcohols (e.g., teichoic acids).
  • whole cell is meant a chemically fixed bacterial or fungal cell. Fixation may be accomplished through exposure to an aldehyde containing compound such as formaldehyde, paraformaldehyde, or glutaraldehyde.
  • aldehyde containing compound such as formaldehyde, paraformaldehyde, or glutaraldehyde.
  • the immunogenic conjugates of the present invention are simple to make, less expensive, and more adaptive to different antigens of interest and carrier proteins than existing conjugate technologies. No capsular antigens need be purified to produce these conjugate immunogens. Because the immunogens are prepared on the surface of fixed cells, the microbial pathogen is irreversibly inactivated before synthesis of the conjugate is performed. Fixation can be accomplished through exposure to aldehyde containing compounds such as
  • the immunogenic conjugates of the present invention do not require that each combination of carrier protein and the antigen intended to evoke an immune response be conjugated by a tailored ligation process unique to their respective chemical properties.
  • the present invention simplifies the method of making these conjugates from inactivated whole microbial cells, and carrier protein that does not need to be highly purified in order to react with whole cells activated by the described procedures. Hence, the present invention and reduces the cost of their preparation compared to current immunogenic conjugate technology.
  • the immunogenic conjugates of the present invention also address a need for immunogenic conjugates that can safely induce immunity against previously intractable antigens. Immunogenic conjugates containing TLR (Toll-like receptor) ligands have been shown to evoke immune responses for otherwise intractable antigens, but they tend to be unsafe because TLR ligands are often
  • FIG. 1 is a scheme showing CDAP- or BrCN-mediated activation of the surface of a fixed whole cell, followed by covalent linking a carrier protein to the activated surface of the fixed whole cell.
  • FIG. 2A is a FITC/SSC dot plot for pneumococcal PS4 cells treated with CDAP.
  • FIG. 2B is a FITC/SSC dot plot for pneumococcal PS4 cells treated with CDAP and with hydrazine-activated CRM1 97 protein.
  • FIG. 3A is an electron micrograph of untreated pneumococcal PS4 whole cells exposed to gold nanoparticles against CRM197.
  • FIG. 3B is an electron micrograph of pneumococcal PS4 whole cells treated with the hydrazine- activated CRM197 and exposed to gold nanoparticles against CRM197.
  • FIG. 3C is an electron micrograph of pneumococcal PS4 whole cells treated with CDAP and exposed to gold nanoparticles against CRM1 97.
  • FIG. 3D is an electron micrograph of pneumococcal PS4 whole cells treated with both CDAP and the hydrazine-activated CRM197 and then exposed to gold nanoparticles against CRM197.
  • FIG. 4 is a chart showing anti-PPS4 IgG titers at various dilutions for mice immunized with PBS control (PBS), formalin-fixed pneumococcal PS4 whole cells (FX), PPS4-CRM197 conjugates (CRM), and PREVNAR 13® vaccine (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) (PREVNAR).
  • PBS PBS control
  • FX formalin-fixed pneumococcal PS4 whole cells
  • CCM197 conjugates CCM
  • PREVNAR 13® vaccine Pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]
  • FIG. 5A is an image showing a Western blot analysis of CDAP mediated conjugation between a purified PPS4 capsule and hydrazine-labeled peptide. Different conditions were assayed, separated on 4-12% gradient SDS-PAGE, and immunoblotted against PPS4 (Green) and peptide (HA; Red).
  • FIG. 5B is an image showing Western blot analysis of CDAP mediated conjugation between a fixed whole PPS4 cell and hydrazine-labeled peptide. Different conditions were assayed, separated on 4- 12% gradient SDS-PAGE, and immunoblotted against PPS4 (Green) and peptide (HA; Red).
  • FIG. 6A is an image showing immunogold electron microscopy visualization of unmodified, fixed PPS4 cells.
  • FIG. 6B is an image showing immunogold electron microscopy visualization of CDAP-treated, fixed PPS4 cells.
  • FIG. 6C is an image showing immunogold electron microscopy visualization of unmodified, fixed PPS4 cells incubated with hydrazine-SGSGSLPETGGYPYDVPDY (SEQ ID NO: 1 ).
  • FIG. 6D is an image showing immunogold electron microscopy visualization of CDAP-treated, fixed PPS4 cells incubated with hydrazine-SGSGSLPETGGYPYDVPDY (SEQ ID NO: 1 ).
  • FIG. 7 is a series of fluorescence microscopy images showing: in row A, untreated fixed cells; in row B, CDAP-treated cells; in row C, unmodified fixed cells incubated with hydrazine- SGSGSLPETGGYPYDVPDY (SEQ ID NO: 1 ); and, in row D, CDAP-treated fixed cells incubated with hydrazine-SGSGSLPETGGYPYDVPDY (SEQ ID NO: 1 ).
  • the data in FIG. 7 demonstrate no significant loss of DNA in CDAP activated cells.
  • FIG. 8A is an image showing Western blot analysis of CDAP-mediated conjugation between fixed
  • PPS4 cells and hydrazine activated CRM197 Separation is on 4-12% gradient SDS-PAGE, and immunoblotted against PPS4.
  • FIG. 8B is an image showing Western blot analysis of CDAP-mediated conjugation between fixed PPS4 cells and hydrazine activated CRM197. Separation is on 4-12% gradient SDS-PAGE, and immunoblotted against CRM197.
  • MFI mean fluorescent intensity
  • FIG. 10A is an immunogold electron microscopy image of fixed, whole PPS4 cells.
  • FIG. 10B is an immunogold electron microscopy image of fixed, whole PPS4 cells incubated with hydrazine activated CRM197.
  • FIG. 10C is an immunogold electron microscopy image of CDAP-activated, fixed, whole PPS4 cells incubated with hydrazine activated CRM197.
  • FIG. 10D is an immunogold electron microscopy image of CDAP-activated, fixed, whole PPS4 cells incubated with hydrazine activated CRM197 without primary antibody incubation.
  • FIG. 1 1 A is a chart showing ELISA response curves of serially diluted, enumerated samples towards CRM197.
  • the enumerated samples are as follows: (1 ) fixed whole cells, (2) CDAP-treated cells, (3) activated CRM197 incubated with fixed whole cells, (4) CDAP-treated cells incubated with hydrazine activated CRM197, and (1 0x) is a 10x scale up of conjugations.
  • the quantification is ELISA-based.
  • the tests were performed by assaying serially diluted samples for the presence of CRM197 (detection: AP- conjugated IgG secondary antibody; and visualization: by incubation with PNPP substrate detection at 405nm).
  • FIG. 1 1 B is a chart quantifying ELISA responses of serially diluted, enumerated samples towards
  • CRM197 compared to a CRM197 standard curve.
  • the enumerated samples are as follows: (1 ) fixed whole cells, (2) CDAP-treated cells, (3) activated CRM197 incubated with fixed whole cells, (4) CDAP- treated cells incubated with hydrazine activated CRM1 97, and (10x) is a 10x scale up of conjugations.
  • the quantification is ELISA-based. The tests were performed by assaying serially diluted samples for the presence of CRM197 (detection: AP-conjugated IgG secondary antibody; and visualization: by incubation with PNPP substrate detection at 405nm).
  • FIG. 12A is a chart showing ELISA response curves of serially diluted, enumerated samples towards Ply * .
  • the enumerated samples are as follows: (1 ) fixed whole cells, (2) CDAP-treated cells, (3) activated Ply * incubated with fixed whole cells, (4) CDAP-treated cells incubated with hydrazine activated Ply * , and (10x) is a 10x scale up of conjugations.
  • the quantification is ELISA-based.
  • the tests were performed by assaying serially diluted samples for the presence of Ply * (detection: AP-conjugated IgG secondary antibody; and visualization: by incubation with PNPP substrate detection at 405nm).
  • FIG. 12B is a chart quantifying ELISA responses of serially diluted, enumerated samples towards
  • Ply * The enumerated samples are as follows: (1 ) fixed whole cells, (2) CDAP-treated cells, (3) activated Ply * incubated with fixed whole cells, (4) CDAP-treated cells incubated with hydrazine activated Ply * , and (1 Ox) is a 1 0x scale up of conjugations.
  • the quantification is ELISA-based. The tests were performed by assaying serially diluted samples for the presence of Ply * (detection: AP-conjugated IgG secondary antibody; and visualization: by incubation with PNPP substrate detection at 405nm).
  • FIG. 13 is a chart showing survival curves of mice in IP challenge against PPS4. Groups of 8 mice were infected with 1 .7x10 7 CFU PPS4 whole cells and monitored for the disease progression.
  • FIG. 14A is a FACS density plot showing consistent cell size by area for flow cytometrically analyzed CDAP-activated PPS4 cells before the CRM197 conjugation.
  • FIG. 14B is a FACS density plot showing consistent single cell size width for flow cytometrically analyzed CDAP-activated PPS4 cells before the CRM197 conjugation.
  • FIG. 14C is a FACS density plot showing anti-CRM197 antibody response to CDAP-activated PPS4 cells for flow cytometrically analyzed CDAP-activated PPS4 whole cells before the CRM197 conjugation.
  • FIG. 14D is a FACS density plot showing consistent cell size by area for flow cytometrically analyzed PPS4-CRM197 whole cell conjugates.
  • FIG. 14E is a FACS density plot showing consistent single cell size width for flow cytometrically analyzed PPS4-CRM197 conjugated cells.
  • FIG. 14F is a FACS density plot showing anti-CRM197 antibody response to PPS4-CRM1 97 whole cell conjugates for flow cytometrically analyzed PPS4-CRM197 conjugated cells.
  • FIG. 15A is a chart showing ELISA response curves of CDAP-activated PPS4 whole cells to the varied quantity of added CRM197.
  • FIG. 15B is a chart quantifying ELISA responses of CDAP-activated PPS4 whole cells to the varied quantity of added CRM197.
  • FIG. 16A is a chart showing ELISA response curves of PPS4 whole cells to the varied volume of the PPS4 resuspended sample.
  • FIG. 16B is a chart quantifying ELISA responses of PPS4 whole cells to the varied volume of the PPS4 resuspended sample.
  • FIG. 17A is a chart showing ELISA response curves of PPS4-CRM1 97 conjugated cells to the variation in the conjugation volume.
  • FIG. 17B is a chart quantifying ELISA responses of PPS4-CRM197 conjugated cells to the variation in the conjugation volume.
  • FIG. 18 is a chart showing anti-CRM197 titers at various dilutions for mice immunized with an adjuvant (control), formalin-fixed pneumococcal PS4 whole cells, PPS4-CRM197 whole cell conjugates, PPS4-Ply whole cell conjugates, and PREVNAR 13® vaccine (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM1 97 protein]).
  • FIG. 19 is a chart showing anti-Ply * titers at various dilutions for mice immunized with an adjuvant (control), formalin-fixed pneumococcal PS4 whole cells, PPS4-CRM197 whole cell conjugates, PPS4-Ply whole cell conjugates, and PREVNAR 13® vaccine (Pneumococcal 13-valent conjugate vaccine
  • FIG. 20 is a chart showing anti-PPS4 IgG titers at various dilutions for mice immunized with an adjuvant (control), formalin-fixed pneumococcal PS4 whole cells, PPS4-CRM197 whole cell conjugates, PPS4-Ply whole cell conjugates, and PREVNAR 13® vaccine (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM1 97 protein]).
  • FIG. 20 is a chart showing anti-PPS4 IgG titers at various dilutions for mice immunized with an adjuvant (control), formalin-fixed pneumococcal PS4 whole cells, PPS4-CRM197 whole cell conjugates, PPS4-Ply whole cell conjugates, and PREVNAR 13® vaccine (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM1 97 protein]).
  • FIG. 20 is a chart showing anti-PPS4 IgG titers at various d
  • 21 is a chart showing anti-PPS4 lgG1 * titers at various dilutions for mice immunized with an adjuvant (control), formalin-fixed pneumococcal PS4 whole cells, PPS4-CRM197 whole cell conjugates, PPS4-Ply whole cell conjugates, and PREVNAR 13® vaccine (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM1 97 protein]).
  • FIG. 22 is a chart showing anti-PPS4 lgG2b titers at various dilutions for mice immunized with an adjuvant (control), formalin-fixed pneumococcal PS4 whole cells, PPS4-CRM197 whole cell conjugates, PPS4-Ply whole cell conjugates, and PREVNAR 13® vaccine (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM1 97 protein]).
  • FIG. 23 is a chart showing anti-PPS4 lgG3 titers at various dilutions for mice immunized with an adjuvant (control), formalin-fixed pneumococcal PS4 whole cells, PPS4-CRM197 whole cell conjugates, PPS4-Ply whole cell conjugates, and PREVNAR 13® vaccine (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM1 97 protein]).
  • FIG. 24 is a scheme showing conjugation of biotin to a whole cell.
  • FIG. 25A is an image for the Western blot analysis of CDAP-mediated conjugation between fixed PPS4 whole cells and NHS-PEG4-Biotin. Separation is on 4-12% gradient SDS-PAGE, and
  • FIG. 25B is an image for the Western blot analysis of CDAP-mediated conjugation between fixed PPS4 whole cells and NHS-PEG4-Biotin. Separation is on 4-12% gradient SDS-PAGE, and
  • FIG. 26A is an image showing immunogold electron microscopy visualization of unmodified, fixed PPS4 whole cells.
  • FIG. 26B is an image showing immunogold electron microscopy visualization of CDAP-treated, fixed PPS4 whole cells conjugated to biotin using NHS-PEG4-Biotin.
  • FIG. 27 is a scheme illustrating a non-limiting example of the preparation and purification of a polyol antigen-carrier protein conjugate via a whole cell-carrier protein conjugate.
  • the invention provides whole cell-protein conjugates and methods of making and administering such compositions to provide immunity against T-cell independent antigens or antigens which normally invoke weak immune responses (e.g., polyol antigens, such as polysaccharides and polyalcohols).
  • the whole cell-protein conjugates of the invention include a carrier protein and a whole cell having an exterior surface including a polyol antigen that is covalently linked to the carrier protein.
  • the whole cell-protein conjugates of the invention include a carrier protein and whole cell having an exterior surface including a polyol antigen that is linked to the carrier protein through a linker including a complementary affinity pair.
  • the carrier protein can effectively display and facilitate a robust immune response to the polyol antigen.
  • the immune response to the polyol antigen can also be enhanced in the immunogenic conjugate relative to the isolated polyol antigen or relative to the whole cell having an exterior surface including an unconjugated polyol antigen.
  • the invention also provides a method of preparing immunogenic polyol antigen-protein conjugates via whole cell-protein conjugates; this method permits preparation of immunogenic polyol antigen-protein conjugates with only a simple purification (e.g., affinity purification) of the polyol antigen- protein conjugates.
  • this method takes advantage of the conjugated protein to purify the polyol antigen-protein conjugate away from unconjugated cellular components in contrast to the complex purification techniques required for separation of an unconjugated polyol antigen from unconjugated cellular components produced by lysis of whole cells having an exterior surface including the unconjugated polyol antigen.
  • Cell lysis methods are known in the art.
  • Non-limiting examples of cell lysis methods include mechanical disruption methods, for example, freeze/thaw cycling, sonication, pressure, or filtration. Alternatively, enzymatic as well as detergent-mediated cell lysis methods are also known in the art.
  • Polysaccharides are polymers of saccharides (sugars). PS derived from capsules are the primary antigenic components involved in protective immunity against encapsulated bacterial pathogens, such as Neisseria meningitidis, Streptococcus pneumoniae, Salmonella typhi, and Haemophilus influenzae Type B.
  • Immunization of adolescents and adults with immunogenic conjugates based on microbial PS has been successful in reducing disease burden, but has proven less effective in providing protective immunity to infants and young children (i.e., children less than 24 months of age). Young children have not yet developed a mature adaptive immune repertoire and T cell-independent antigens, such as capsular PS, are poorly immunogenic and do not lead to long-term protective immune responses (i.e., an immunological memory response) in such young immunogenic conjugate recipients.
  • a T-cell independent antigen such as PS
  • PS can be converted to a T-cell dependent antigen by chemical coupling of PS to protein; this process is called “conjugation” and involves the formation of covalent bonds between atoms in the PS structure and side chain atoms of amino acids present in the "carrier” protein.
  • conjugates more efficiently promote the induction of B-cell maturation and isotype switching leading to much higher levels of antibody with the correct anti-PS protective profile.
  • Protective antibodies have high affinity for their PS antigens and typically are of the Immunoglobulin G (IgG) subclass— a long-lived antibody with complement fixing and opsonic effector activity.
  • IgG Immunoglobulin G
  • a typical pathway for induction of an anti-PS IgG immune response can be exemplified by a conjugate containing a PS and tetanus toxoid as the carrier protein.
  • the carrier protein is bound to the surface of the B-cell that displays the correct PS binding specificity.
  • the carrier protein-PS complex is taken up by these B-cells into the intracellular vacuolar compartment where the carrier is processed by proteolytic degradation.
  • Peptides derived from the carrier protein are transported and loaded into the presentation groove of the MHC- Class I I receptor (MHC-II).
  • This MHC-l l-carrier peptide complex is displayed on the surface of the B-cell.
  • TCR T-cell receptor
  • T-cells Upon recognition of the MHC-l l-peptide complex by the T-cell receptor (TCR), T-cells become activated and secrete cytokines that provide "help" for the induction of B-cell differentiation. B-cells expand in numbers and differentiate into "plasma cells” which now secrete antibody. Initially Immunoglobulin M (IgM) is produced by plasma cells but eventually the T-cell help cause the plasma cells to class switch and produce other isotype classes of antibody such as IgG. This process continues with plasma cells undergoing mutational changes leading to production of antibody receptors that have even higher affinity for the PS-carrier protein conjugates.
  • IgM Immunoglobulin M
  • Memory B-cells which are long lived and specific for the PS.
  • Memory B-cells have a unique property in that they can be immediately activated if exposed to PS. Activation causes memory B-cells to multiply and quickly produce anti-PS IgG .
  • the activation of memory B cells that occurs during a second exposure of to PS antigen is called a "booster response" and is indicative of a long lived “secondary” memory immune response.
  • Primary immunization may stimulate the production of IgM antibodies and some IgG antibodies.
  • secondary immunization i.e., the "booster" shot, memory cells already programmed by the first immunization are stimulated to produce large quantities of IgG, the memory immune response.
  • a T-cell independent antigen generally does not stimulate lasting immunity, i.e., the production of IgG antibodies, but may stimulate the production of less potent and more temporary IgM antibodies.
  • polyol antigens alone do not typically produce booster responses of IgG .
  • polyol antigens do produce booster responses if primary immunization is performed with a conjugate containing a polyol antigen and a carrier protein because memory cells induced by the conjugate have already been programmed to produce IgG.
  • conjugates containing a polyol antigen and a carrier protein are valued for (1 ) their ability to induce high levels of IgG against polyol antigens, and (2) their ability to induce memory immune responses against polyol antigens.
  • Unconjugated polyol antigens either isolated or as part of a whole cell typically do not display these properties and thus are inferior antigens.
  • the difficulty in synthesizing immunogenic conjugates and their cost of production has slowed the development of immunogenic conjugates for many bacterial diseases where an immune response to polyol antigen may be protective.
  • TLRs Toll-like receptors
  • LPS lipopolysaccharides
  • Carrier proteins used in the immunogenic conjugates of the invention desirably are proteins that, either alone or in combination with an antigen, invoke an immune response in a subject.
  • the carrier protein contains at least one epitope recognized by a T-cell.
  • the epitope is capable of inducing a T-cell response in a subject, and induce B-cells to produce antibodies against the entire antigen of interest.
  • Epitopes as used in describing this invention include any determinant on an antigen that is responsible for its specific interaction with an antibody molecule or fragment thereof.
  • Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and have specific three-dimensional structural characteristics as well as specific charge characteristics.
  • a protein or polypeptide generally is capable of stimulating T-cells.
  • a carrier protein that lacks an epitope recognized by a T-cell may also be immunogenic.
  • the carrier protein desirably is sufficiently foreign to elicit a strong immune response to the immunogenic conjugate.
  • the carrier protein used is a molecule that is capable of imparting immunogenicity to the antigen of interest.
  • a carrier protein is one that is inherently highly immunogenic.
  • a carrier protein that has a high degree of immunogenicity and is able to maximize antibody production to the antigens complexed with it is desirable.
  • Various carrier proteins of the invention include, e.g., toxins and toxoids (chemical or genetic), which may or may not be mutant, such as anthrax toxin, PA and DNI (PharmAthene, Inc.), diphtheria toxoid (Massachusetts State Biological Labs; Serum Institute of India, Ltd.) or CRM 197, tetanus toxin, tetanus toxoid (Massachusetts State Biological Labs; Serum Institute of India, Ltd.), tetanus toxin fragment Z, exotoxin A or mutants of exotoxin A of Pseudomonas aeruginosa, bacterial flagellin, pneumolysin, an outer membrane protein of Neisseria meningitidis (strain available from the ATCC (American Type Culture Collection, Manassas, Va.)), Pseudomonas aeruginosa Hcp1 protein,
  • the carrier protein is the cholera toxin B subunit (available from SBL Vaccin AB), diphtheria toxin (Connaught, Inc.), tetanus toxin Fragment C (available from Sigma Aldrich), DNI, or beta-galactosidase from Escherichia coli (available from Sigma Aldrich).
  • Other desirable carrier proteins include bovine serum albumin (BSA), P40, and chicken riboflavin.
  • exemplary carrier proteins are commercially available from Sigma Aldrich.
  • Other exemplary carrier proteins are MAPs (multi-antigenic peptides), which are branched peptides. By using a MAP, cross-linking density is maximized because of multiple branched amino acid residues.
  • An exemplary amino acid that can be used to form a MAP is, but is not limited to, lysine.
  • Carrier proteins also include those from non-human source such as keyhole limpet hemocyanin (KLH). Mutant forms of all the above proteins are also included, in particular, if the mutation ablates toxicity or removes epitopes that immunologically cross-react with human proteins. These can be engineered for production through standard genetic techniques by investigators skilled in the art of protein engineering.
  • Carrier proteins which have been used in the preparation of therapeutic immunogenic conjugates include, but are not limited to, a number of toxins of pathogenic bacteria and their toxoids. Examples include diphtheria and tetanus toxins and their medically acceptable corresponding toxoids. Other candidates are proteins antigenically similar to bacterial toxins referred to as cross-reacting materials (CRMs). Carrier proteins of the invention may also include any protein not derived from humans and not present in any human food substance.
  • DNI is used as the carrier protein because it is nontoxic leaving no need to detoxify the protein before use. Furthermore, the use of DNI is desirable because DNI may also induce a protective immune response to B. anthracis, in addition to the protective immune response to the antigen of interest.
  • the immunogenic conjugate of the invention and the related compositions and methods of the invention can be used with any polyol antigen (e.g., a polysaccharide antigen or a polyalcohol antigen).
  • polyol antigens include polysaccharides (e.g., polysaccharides having at least 18 residues, or e.g., dextrans, alginates, phosphopolysaccharides, polysaccharides with an amino sugar with an N-acetyl substitution, or polysaccharides containing a sulfonylated sugar, or an O side chain of a lipopolysaccharide) and polyalcohols (e.g., teichoic acids).
  • polysaccharides e.g., polysaccharides having at least 18 residues, or e.g., dextrans, alginates, phosphopolysaccharides, polysaccharides with an amino sugar with an N-acetyl substitution, or
  • Exemplary polyol antigens of interest also include capsular organic polymers including those synthesized by microbes, e.g., bacteria, fungi, parasites, and viruses.
  • Exemplary polyol antigens are those found on the exterior surface of bacterial organisms, such as Bacillus species (including B.
  • the Francisella tularensis polysaccharide may be, e.g., the O antigen.
  • the Streptococcus pneumoniae polysaccharide may be, e.g., one of capsular types described in Kong et al. (J. Med.
  • Streptococcus pneumoniae polysaccharide capsular type may be, e.g., 1 (e.g., 1 -g or 1 -q), 2 (e.g., 2-g, 2-q, or 2-41 A), 3 (e.g., 3-g, 3-q, 3-c, or 3-nz), 4, 5 (e.g., 5-q, 5-c, 5-qap, or 5-g), 6A (e.g., 6A-g, 6A-cl, 6A-c2, 6A-n, 6A-qap, 6A-6B-g, 6A-6B-q, or 6A-6B-S), 6B (e.g., 6B-c, 6A-6B-g, 6A-6B- q, or 6A-6B-S), 7F (e.g., 7F-7A), 7A (e.g., 7A-cn or 7F-7A), 7B (e.g., 7B (e.g., 7B
  • exemplary antigens of interest include killed whole cell encapsulated pathogens such as Bacillus species (including B. anthracis) (Wang and Lucas, Infect. Immun. 72(9):5460-5463, 2004), Streptococcus pneumoniae (Bentley et al., PLoS Genet. 2(3):e31 , Epub 2006; Kolkman et al., J. Biochemistry 123:937-945, 1998; and Kong et al., J. Med. Microbiol. 54:351 -356, 2005), Shigella (Zhao et al., Carbohydr. Res.
  • Bacillus species including B. anthracis
  • Streptococcus pneumoniae Bentley et al., PLoS Genet. 2(3):e31 , Epub 2006
  • Kolkman et al. J. Biochemistry 123:937-945, 1998
  • Kong et al. J. Med. Microbiol. 54:351 -356
  • the immunogenic whole cell-protein conjugate of the invention can include a carrier protein and a whole cell having an exterior surface including a polyol antigen that is covalently linked to the carrier protein through a linker.
  • the linker can be formed by a reaction between a cyanate group bonded to the polyol antigen and a hydrazine-activated carrier protein.
  • the linker can be represented by a formula:
  • Z 2 is a bond to a carbonyl group in the carrier protein
  • Z 3 is O or NH
  • each of n and m is 0 or 1 , and
  • L when present, is C2-6 alkanediyl or Ce- ⁇ arenediyl.
  • the conjugation of a polyol antigen to a carrier protein may be performed using a cyanylation- mediated conjugation method. Specifically, contacting an antigen-cyanate with a hydrazine-activated carrier protein can produce a conjugate, where the antigen is linked to the carrier protein through the linker Z 1 -C(Z 3 )-N(H)-N(H)-(-C(0)-(L-C(0)) n -N(H)-N(H)-) m -Z 2 .
  • the antigen-cyanate can be prepared through the cyanylation of the antigen with an electrophilic source of cyanide (e.g., cyanogen bromide or CDAP).
  • the hydrazine-activated carrier protein can be prepared by reacting the carrier protein with H2N- N(H)-(-C(0)-(L-C(0))n-N(H)-N(H)-)m-H under the reaction conditions known in the art for hydrazide formation.
  • reaction conditions known in the art for hydrazide formation.
  • one non-limiting cyanylation-mediated conjugation protocol includes dissolution of a hydrazine source agent (e.g., dicarboxylic acid dihydrazide, such as succinic acid dihydrazide or adipic acid dihydrazide) in about neutral pH phosphate buffer (e.g., pH of 7.2) containing sodium chloride (e.g., about 0.15M sodium chloride), dissolving a carrier protein in this solution, adding a peptide coupling agent (e.g., 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)), and allowing the resulting reaction mixture to react for a sufficient time period (e.g., about 2 to 4 hours).
  • a hydrazine source agent e.g., dicarboxylic acid dihydrazide, such as succinic acid dihydrazide or adipic acid dihydrazide
  • neutral pH phosphate buffer e.g
  • the resulting modified carrier protein can be purified, e.g., by dialysis or gel filtration using a desalting resin.
  • preparation of a whole cell-carrier protein conjugate can facilitate the preparation of polyol antigen-carrier protein conjugates, as, after the conjugation, the whole cell-carrier protein conjugate can be subjected to lysing conditions known in the art, and the resulting polyol antigen- carrier protein conjugate can be purified away from the unconjugated cellular components using, e.g., affinity purification using solid support having affinity for the carrier protein (e.g., if the carrier protein includes one or more affinity purification tags, or if the solid support includes antibodies specific to the carrier protein).
  • FIG. 27 A non-limiting example of the preparation of polyol antigen-carrier protein conjugates is illustrated in FIG. 27.
  • Whole cells may be killed by a chemical, e.g., formaldehyde, treatment or by heat- inactivation and subsequently conjugated as described herein.
  • a chemical e.g., formaldehyde
  • polyol antigens can be coupled to a carrier protein, or a mixture of carrier proteins can be conjugated to the polyol antigen; both of these options may be achieved in a single reaction or multiple sequential reactions.
  • the method described herein permits multiplexing of the immunogenic conjugate, further reducing the cost of production.
  • Tetanus toxoid is one possible carrier protein. This toxin is detoxified by treatment with formaldehyde, a reagent that reacts with amino groups of proteins.
  • Other desirable carrier proteins include the cholera toxin B subunit (available from SBL Vaccin AB), diphtheria toxin, tetanus toxin Fragment C (available from Sigma Aldrich), DNI, or beta-galactosidase from
  • Escherichia coli available from Sigma Aldrich.
  • the immunogenic conjugates of the invention may be used to immunize against, for example, Pneumococcus infection, Streptococcus (groups A and B) infection, Haemophilus influenzae type B ("HiB") infection, meningococcal (e.g., Neisseria meningitides) infection, and may be used as O antigen immunogenic conjugates from Gram negative bacteria (e.g., Pseudomonas aeruginosa, Francisella tularensis (Thirumalapura et al., J. Med. Microbiol. 54:693-695, 2005; Vinogradov and Perry, Carbohydr. Res.
  • Gram negative bacteria e.g., Pseudomonas aeruginosa, Francisella tularensis (Thirumalapura et al., J. Med. Microbiol. 54:693-695, 2005; Vinogradov and Perry, Carbohydr. Res.
  • covalent linkers that may be used in the whole cell-carrier protein conjugates of the invention described herein.
  • the linker can be formed by a reaction between an aldehyde group (-CHO) and an amino group (-NH2) in a carrier protein or a hydrazine-activated carrier protein.
  • the linker can be represented by a formula:
  • Z 5 is a bond the carrier protein
  • each of n, m, and k is independently 0 or 1 , and
  • L when present, is C2-6 alkanediyl or Ce- ⁇ arenediyl.
  • the aldehyde group can be introduced into the polyol antigen having a vicinal diol moiety (e.g., as found in a polysaccharide antigen) using reactions and reaction conditions known in the art.
  • a non- limiting example of a reaction whereby an aldehyde group is introduced into a polyol antigen includes a diol cleavage using sodium periodate.
  • the linker can be formed through a thioether formation.
  • the linker can be represented by a formula:
  • Z 1 -C(0)-N(H)-(N(H))k-L-N(H)-C(0)-CH 2 -S-L 1 -C(0)-Z 2 where Z 1 is a bond to an oxygen atom in the polyol antigen, Z 2 is a bond to an amino group (e.g. , N-terminus or a side chain amino) in the carrier protein, k is 0 or 1 ,
  • L is C2-6 alkanediyl
  • L 1 is C2-6 alkanediyl optionally substituted with a protected amino group.
  • L 1 C 2- 6 alkanediyl optionally substituted with a protected amino group
  • the linker can be formed through a reaction sequence including reductive amination and amidation.
  • the linker can be represented by a formula:
  • Z 5 is a bond the carrier protein
  • L is C2-6 alkanediyl or Ce- ⁇ arenediyl.
  • reaction sequence including reductive amination and amidation is shown in the following scheme.
  • the linker can be formed through a thiol-maleimide conjugation.
  • the linker can be represented by a formula:
  • Z 2 is a bond to an amino group (e.g., N-terminus or a side chain amino) in the carrier protein, each L is independently C2-6 alkanediyl, and
  • L 1 is C2-6 alkanediyl.
  • the linker can be formed through a reaction between a cyanylated polyol antigen and a carrier protein.
  • the linker can be represented by a formula:
  • Z 1 is a bond to an oxygen atom in the polyol antigen
  • Z 2 is a bond to a carrier protein
  • R polyol antigen
  • the linker can be formed using click chemistry (e.g., [3+2] dipolar cycloaddition).
  • click chemistry e.g., [3+2] dipolar cycloaddition.
  • the linker can be represented by a formula:
  • Z 2 is a bond to an amino group (e.g., N-terminus or a side chain amino) in the carrier protein, and each of L and L 1 is independently C2-6 alkanediyl.
  • a non-limiting example of [3+2] dipolar cycloaddition-based conjugation is shown in the following scheme.
  • the immunogenic whole cell-protein conjugate of the invention can include a carrier protein and a whole cell having an exterior surface including a polyol antigen that is linked to the carrier protein through a linker containing a complementary affinity pair.
  • the linker can be represented by a formula:
  • Z 2 is a bond to a carrier protein
  • Z 3 is O or NH
  • L is C2-10 alkanediyl or -[-CH2-CH2-(-0-CH2-CH2-)n]-, where n is an integer from 0 to 24, L 1 is -N(H)- or -N(H)-N(H)-,
  • L 2 is -N(H)-, -C(O)-, -C(0)-N(H)-, or -N(H)-C(0)-,
  • AP is a complementary affinity pair.
  • the complementary affinity pair may be a biotin/streptavidin, biotin/avidin, biotin/neutravidin, maltose binding protein/maltose, or maltose binding protein/maltotriose pair.
  • One component of a complementary affinity pair may be covalently linked to the polyol antigen, and the complementary component from the said pair may be covalently linked to the carrier protein.
  • the affinity pair-based linker can be formed by contacting such polyol antigen and carrier protein.
  • biotin may be covalently linked to the polyol antigen
  • streptavidin, avidin, or neutravidin may be covalently linked to the carrier protein.
  • a carrier protein linked to streptavidin, avidin, or neutravidin may be a fusion protein.
  • Such fusion proteins may be prepared using techniques known in the art (e.g., recombinant fusion protein preparation).
  • maltose binding protein/maltose or maltose binding protein/maltotriose pair When maltose binding protein/maltose or maltose binding protein/maltotriose pair is used, maltose or maltotriose may be covalently linked to the polyol antigen, and maltose binding protein may be covalently linked to the carrier protein.
  • a carrier protein linked to maltose binding protein may be a fusion protein.
  • Such fusion proteins may be prepared using techniques known in the art (e.g., recombinant fusion protein preparation).
  • Polyol antigen-protein conjugates are difficult to produce cost-effectively because of the specialized chemistry required for their preparation and purification.
  • Polyol antigen-protein conjugation by covalent linkage procedures have numerous drawbacks, including the need for either synthetic preparation of polyol antigens or for isolation of polyol antigens from cell lysates. Both approaches dramatically increase cost of manufacture of polyol antigen-protein conjugates.
  • the polyol antigen-protein conjugate can be prepared from a whole cell-protein conjugate through lysing the whole cells in the whole cell-protein conjugate according to methods known in the art and purifying the resulting polyol antigen-protein conjugate away from the unconjugated cellular components.
  • the purification may include affinity purification, e.g., using metal ions immobilized on solid support, if the protein contains one or more poly- His tags, or using immunoprecipitation techniques (e.g., techniques utilizing a solid support having immobilized antibodies capable of binding to the carrier protein).
  • this method of the invention takes advantage of the carrier protein structure to separate out the polyol antigen, which, typically otherwise, would require either a costly chemical preparation or a costly, complex purification using techniques known in the art.
  • the immunogenic conjugates of the invention may be used in combination, for example, in pediatric immunizations.
  • the immunogenic conjugates of the invention may be used to immunize against, for example, Pneumococcus infection, Haemophilus influenzae type B ("HiB") infection, Streptococcus (groups A and B) infection, meningococcal (e.g., Neisseria meningitides) infection, and may be used as O antigen immunogenic conjugates from Gram negative bacteria (e.g., Pseudomonas aeruginosa, Francisella tularensis, Shigella species, Salmonella species, Acinetobacter species, Burkholderia species, and Escherichia coli).
  • Gram negative bacteria e.g., Pseudomonas aeruginosa, Francisella tularensis, Shigella species, Salmonella species, Acinetobacter species, Burkholderia species, and Escherichia coli).
  • the immunogenic conjugate formulation desirably includes at least one immunogenic conjugate of the invention and a pharmaceutically acceptable carrier or excipient (e.g., aluminum phosphate, sodium chloride, or sterile water).
  • An immunogenic conjugate composition may also include an adjuvant system for enhancing the immunogenicity of the formulation, such as oil in a water system and other systems known in the art or other pharmaceutically acceptable excipients.
  • An immunogenic conjugate that is insoluble under physiological conditions is desirable to slowly release the antigen after administration to a subject. Such a complex desirably is delivered in a suspension containing pharmaceutically acceptable excipients.
  • the immunogenic conjugate of the invention may also be soluble under physiological conditions.
  • the immunogenic conjugate may be provided in a volume of about 0.5 mL for subcutaneous injection, 0.1 mL for intradermal injection, or 0.002-0.02 mL for percutaneous
  • a 0.5 mL dose of the immunogenic conjugate may contain approximately 2-500 ⁇ g of the antigen covalently linked with approximately 2-500 ⁇ g of the carrier protein.
  • approximately 10 ⁇ g of the antigen are conjugated with approximately 10 ⁇ g of the carrier protein.
  • the molar ratio of a polyol antigen to carrier protein desirably is 1 :1 (e.g., 1 part polyol antigen to 1 part carrier protein).
  • the formulation includes at least one immunogenic conjugate and a pharmaceutically acceptable buffer (e.g., bicarbonate buffer) as a pharmaceutically acceptable carrier for neutralization of gastric acid.
  • a pharmaceutically acceptable buffer e.g., bicarbonate buffer
  • the immunogenic conjugate preparation is mixed with a buffer, e.g., 5.6 g of sodium hydrogen carbonate granules dissolved in 150 mL of sterile water.
  • the immunogenic conjugate contains about 1 mg of whole cell pathogen immunogenic conjugate in a single dose for oral administration.
  • a 1 mg dose of the immunogenic conjugate may contain at least 1 x 1 0 9 whole cell pathogens or a range of 1 x 10 9 to 1 x 10 1 1 whole cell pathogens covalently linked with approximately 2-500 ⁇ g of the carrier protein.
  • the immunogenic conjugates of the invention may be administered to a subject enterally (for instance, by oral administration) by ingestion of an immunogenic conjugate in the form of a e.g., liquid, powder, capsule, or tablet.
  • Immunogenic conjugates of the invention may be administered, one or more times, often including a second administration designed to boost production of antibodies in a subject to prevent infection by an infectious agent.
  • the frequency and quantity of immunogenic conjugate dosage depends on the specific activity of the immunogenic conjugate and can be readily determined by routine experimentation.
  • the age at which the first dosage is administered generally is two-years.
  • the immunogenic conjugates of the invention may be administered according to the following exemplary schedule.
  • a booster dose is desirably given as early as six months following the last dose in subjects who are at a high risk for infection; or five years after the last dose to previously immunized adults and children above two years of age.
  • the immunogenic conjugate may be desirably administered parenterally (e.g., by subcutaneous,
  • the immunogenic conjugates of the invention can also be administered by transdermal or transmucosal absorption.
  • the immunogenic conjugates of the invention may be administered to a subject, e.g., by intramuscular injection, intradermal injection, or transcutaneous immunization with appropriate immune adjuvants.
  • Immunogenic conjugates of the invention may be administered, one or more times, often including a second administration designed to boost production of antibodies in a subject to prevent infection by an infectious agent.
  • the frequency and quantity of immunogenic conjugate dosage depends on the specific activity of the immunogenic conjugate and can be readily determined by routine experimentation. While the age at which the first dosage is administered generally is two-months, an immunogenic conjugate may be administered to infants as young as six weeks of age. For children who are beyond the age of a routine infant vaccination schedule, the immunogenic conjugates of the invention may be administered according to the following exemplary schedule.
  • a booster dose is desirably given as early as four years following the last dose in subjects who are at a high risk for infection; or 1 0 years after the last dose to previously immunized adults and children above fifteen years of age.
  • Immunogenic conjugates of the invention can be formulated in pharmacologically acceptable vehicles, e.g., alum hydroxide gel, adjuvant preparation, or saline, and then administered, e.g., by intramuscular injection, intradermal injection, or transcutaneous immunization with appropriate immune adjuvants.
  • pharmacologically acceptable vehicles e.g., alum hydroxide gel, adjuvant preparation, or saline
  • kits that include an immunogenic conjugate described herein.
  • kits of the invention can also include instructions for using the kits in the immunization methods described herein.
  • the efficacy of the immunization schedule may be determined by using standard methods for measuring the antibody titer in the subject.
  • mean antibody titers desirably IgG titers
  • IgG titers of approximately 1 ⁇ g/ml are considered indicative of long-term protection.
  • the whole cell-carrier protein conjugates are desirably between 100 nm and 100 ⁇ in diameter.
  • Viruses can be 100 nm in diameter and are immunogenic.
  • Whole bacteria are 1 -10 ⁇ in diameter and are also immunogenic.
  • a small clump of bacteria can be about 100 ⁇ in diameter.
  • CRM197 was hydrazine-activated using adipic acid dihydrazide and 1 - ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) as a coupling agent.
  • EDC ethyl-3-(3-dimethylaminopropyl)carbodiimide
  • the resulting hydrazine- activated CRM197 was purified by size exclusion chromatography.
  • PPS4 formalin-killed pneumococcal PS4 cells
  • PPS4 formalin-killed pneumococcal PS4 cells
  • the CDAP-treated pneumococcal PS4 cells were then treated with the hydrazine-activated CRM1 97 to produce a whole cell PPS4-CRM197 conjugate.
  • the formation of the whole cell PPS4-CRM197 conjugate was confirmed by flow cytometry (see FIGS. 2A and 2B) and electron microscopy using gold nanoparticles against CRM197 (see FIGS. 3A, 3B, 3C, and 3D).
  • the whole cell-carrier protein conjugate preparation through cyanylation-mediated conjugation was also assessed for scalability. As is illustrated in the below table, scaling up the reaction 10-fold did not reduce the recovery of whole cells, as measured by the optical density.
  • mice were immunized by intraperitoneal (I. P.) injections twice with a 3-week rest period with 200 ⁇ _ of PPS4-CRM1 97 prepared in Example 1 , PREVNAR 13® vaccine, or phosphate buffered saline (control). Anti-PPS4 IgG titers were then obtained for these mice (see FIG. 4). As illustrated in FIG. 4, despite lacking adjuvant, PPS4-CRM197 produced anti-PPS4 IgG titers that were comparable to those observed for PREVNAR 13®, which includes an adjuvant. FIG. 4 further shows that anti-PPS4 IgG titers for PPS4-CRM197 were significantly more robust than those observed for unconjugated fixed whole cells.
  • the PS-carrier protein immunogenic conjugate can be modified to further stimulate the immune response, and ultimately improve the efficacy of the immunization, by addition of an adjuvant.
  • the immunogenic conjugate can be absorbed by an alum adjuvant such as aluminum hydroxide gel.
  • the immunogenic can be combined with an emulsion adjuvant such as squalene based oil in water nano emulsion.
  • Adjuvants such as these can be used to create a delivery system for the immunogenic conjugate and function to create depots that trap the conjugated antigen-carrier protein at the site of injection to allow for its slow release. This allows for extended stimulation of the immune system by enabling the immunogenic conjugate to persist at the site of injection, increasing the recruitment and activation of immune cells.
  • PPS4 bacteria were grown on Todd Hewitt with yeast media (THY: 37g/L Todd Hewitt Broth;
  • the proteins carboxylic acids are modified with adipic acid dihydrazide to produce a terminal hydrazide group.
  • the carrier protein was resuspended (5mg/ml_) in 0.1 M sodium phosphate, 0.15M NaCI, pH 7.2.
  • Fresh adipic acid dihydrazide (40mg/ml_) was added, and vortexed thoroughly.
  • 20 mg of 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) was added and vortexed till dissolved.
  • the protein was incubated for 3h at room temperate.
  • the protein was then purified by buffer exchange chromatography, utilizing a PD-10 desalting column (GE healthcare), and resuspended in reaction buffer; 0.1 M Na2B40y1 OH2O (Sodium Borate), 4mM C24H39Na04 (Sodium deoxycholate) pH 9.0.
  • a catalytically dead mutant form of pneumolysin was cloned with a 6-His C terminal epitope into pET100_D-TOPO, and expressed in E. coli.
  • E. coli cells were grown to midlog phase, induced with 1 mM IPTG, and grown for 3 hrs. Cell pellet was resuspended in 50 mL of binding buffer (300mM NaCI, 20mM Tris, 20mM Imidazole, pH 7.8), and cells lysed by cell disruptor (Pressure Biosciences) at 25 kPa. Cell debris was removed by centrifugation, and the supernatant was loaded onto a Ni 2+ -NTA 5ml_ column.
  • the column was washed with wash buffer (300mM NaCI, 20mM Tris, 50mM Imidazole) and eluted with elution buffer (300mM NaCI, 20mM Tris, 500mM Imidazole, pH 7.8). Buffer exchange was utilized to store Ply in 0.1 M sodium phosphate, 0.15M NaCI, pH 7.2
  • the protocol was based on Battaglinia and Pallarola (201 1 ). Briefly, 0.5 mL of 2 mg/mL purified PPS4 capsule was resuspended in 0.1 M sodium borate pH 9.0, 20 ⁇ _ of CDAP (1 OOmg/mL in acetonitrile) was added and vortexed for 30s, followed by 20 ⁇ _ 0.2M triethylamine, and incubated for 1 50 s. 500 [it of hydrazine-activated peptide was incubated with the CDAP activated capsule, and incubated for 2.5 hrs at room temperature with rocking. The reaction is quenched by addition of 50 ⁇ _ 1 M ethanolamine. The conjugate was separated from the non-conjugated peptide by size exclusion chromatography, and stored in PBS. The CDAP-activated, purified PPS4 capsule was analyzed using Western blot (FIG. 5A).
  • Formalin fixed cells were washed with reaction buffer and resuspended at a concentration of 0.1 OD cells/ 0.3mL buffer.
  • CDAP (1 OOmg/mL in acetonitrile) was added at a ratio of 100 mL/ OD cells for 2.5 mins with shaking at room temperature, followed by addition of an equal volume of 0.2M
  • reaction was incubated with shaking for 8 mins, and the cells were pelleted by centrifugation, washed with reaction buffer, and resuspended at a ratio of 0.2 OD/mL reaction buffer.
  • Hydrazine activated peptides or proteins were added to the CDAP activated cells (2mg/ml_) at a ratio of 1 mL/OD bacteria, and incubated for 3h at room temperature with rocking. The excess remaining activated polysaccharides are quenched by adding 200 ⁇ _ 1 M ethanolamine, 1 h at room temperature. Cells were then pelleted and washed for 30 mins with 0.1 % Saponin to remove any unconjugated protein remaining.
  • FIG. 5B shows that elevated levels of the peptide are present in the CDAP-activated cells, thereby suggesting an efficient conjugation between the cell and peptide.
  • FIG. 5B shows that elevated levels of the peptide are present in the CDAP-activated cells, thereby suggesting an efficient conjugation between the cell and peptide.
  • FIG. 6A-6D Similar to the results observed in FIG. 5B, little to no reactivity was observed for unmodified (FIG. 6A) or CDAP activated cells (FIG. 6B), while some reactivity was observed when the peptide was incubated in the absence of CDAP (FIG. 6C). However, CDAP activated cells were found to be coated with immunogold on their surface (FIG. 6D), revealing efficient conjugation. In combination with observations by Western blot, it can be concluded that CDAP can be utilized on formalin fixed cells, and hydrazine activated peptides can be conjugated in an efficient manner.
  • FIGs. 14A- 14F Bacterial cells were gated initially to eliminate debris, followed by a second gating selection for single cell bacteria only (FIGs. 14A- 14F).
  • FIGs. 14C incubation of CDAP activated cells with hydrazine activated CRM resulted in a significant shift in the fluorescence of the population.
  • MFI mean fluorescent intensity
  • PPS4 cells were conjugated in a CDAP dependent manner with Ply * (FIGs. 12A and 12B).
  • Treated PPS4 cells were denatured at 95°C with Bolt sample buffer, separated on an 4-12% SDS-PAGE gel, and transferred to a nitrocellulose membrane.
  • the membrane was blocked for 1 hr in Odyssey blocking buffer (Licor), followed by 1 hr incubation in primary solution; 50% blocking buffer, 50% PBST, anti-PPS4 (SSI ; 16747) and anti-HA (Cell Signaling Technology; 2367S), both at a dilution of 1 /1000.
  • Membranes were washed 3 times with PBST for 5 mins, and incubated in the dark with secondary solution (50% blocking buffer, 50% PBST, IRDye 680 LT Goat anti-mouse and IRDye 800CW goat anti-rabbit both at a dilution of 1 /1 5,000) for 1 hr at room temperature with rocking.
  • the membrane was washed 2x with PBST, one with PBS, and imaged with an Odyssey CLx imaging system.
  • Treated cells were blocked for 1 hr at room temperature with shaking in PBS+ 2mg/ml_ BSA.
  • the cells were subsequently incubated with anti-HA antibody (1 /1 ,000 in 100 ⁇ _ PBST) for 1 hr, washed 3x with PBST, and incubated for 1 hr with Alexa Flor 647 goat anti-mouse IgG (1 /1 ,000; A21235).
  • Stained cells were spotted on a 1 % agar pad containing 3 ⁇ Syto 9, and visualized with a Nikon Eclipse Ti fluorescent microscope.
  • MFI mean fluorescence intensity
  • Cells were then washed 3x 5 mins with PBST, and incubated in 100 ⁇ _ secondary antibody (AlexaFlor 488 goat-anti rabbit, 1 /1000 dilution, Life Technologies) in PBST +2mg/mL BSA for 1 h with shaking in the dark. Cells were washed 3x 5 mins with PBST, resuspended in 1 mL PBST, and analyzed on a BD FACSCanto flow cytometry system.
  • 100 ⁇ _ secondary antibody AlexaFlor 488 goat-anti rabbit, 1 /1000 dilution, Life Technologies
  • the plate was blocked with 125 ⁇ _ PBS+2mg/ml_ BSA for 2 hrs, incubated with primary antibody (anti-CRM; ab53828 or anti-Ply; ab71 810) 1 /5,000 and 1 /4,000 respectively for 2 hrs. Next, washed 3x 5 min with PBST, then secondary antibody incubation for 2 hrs (1 /4,000, goat anti-rabbit IgG-AP Goat anti- mouse IgG-AP; Southern Biotechnologies), washed 3x 5 mins PBST, and visualized by development of colour of PnPP substrate. Protein conjugated to cells was determined via comparison of calculated lines of best fit between protein standard and test group.
  • mice Eight week old female BALB/c mice were purchased from Jackson Labs (Location). All mice were housed in sterile cages and were provided one week for acclimatization prior to the beginning of experiments.
  • mice were immunized by intraperitoneal (I. P.) injections twice with a 3-week rest period with 200 ⁇ _ of (1 ) the vaccine prepared in Example 4 (Wcc-CRM197 or Wcc-Ply) with 0.05% Aluminum phosphate gel adjuvant (Adju-Phos®), or (2) Prevnar (which contains aluminum phosphate adjuvant).
  • I. P. intraperitoneal
  • Example 4 the vaccine prepared in Example 4
  • Adju-Phos® Aluminum phosphate gel adjuvant
  • Prevnar which contains aluminum phosphate adjuvant
  • mice Both Prevnar and Wcc-CRM197 vaccinated mice had robust IgG immune responses against CRM197, whereas only Wcc-Ply mice responded towards Ply. Further, a robust IgG immune response towards an unencapsulated strain of TIGR4 Streptococcus pneumoniae was only observed in mice vaccinated with unmodified fixed whole cells. A low level response was observed for the Wcc-Ply mice, which could be attributed to the naturally occurring Ply in PPS4 cells. The results in Table 2 indicate that Wees produce a robust glycoconjugate-style vaccination response towards the PPS4 capsule, whereas fixed cells can only produce antibodies against cellular proteins.
  • mice were given one week rest after sera collection prior to bacterial challenge.
  • Nunc-lmmunoTM MicrowellTM 96 well plates were incubated with 100 ⁇ _ of antigen per well in 0.1 M Sodium Bicarbonate pH 9.0 (For PPS4 capsule, CRM, and Ply 10 ⁇ g/mL) overnight at 4°C .
  • the plates were then blocked with 125 ⁇ _ PBS with 2% BSA for 3h at room temperature with gentle rocking.
  • murine sera were absorbed with 1 0 ⁇ _/ ⁇ _ purified cell wall polysaccharide (CWPS Multi, SSI68866) in PBST+2% BSA for 3h at room temperature.
  • the absorbed sera were serially diluted at a ratio of V in a 96 well plate with PBST +2% BSA.
  • the blocked antigen plate was washed 3x 5 mins with PBST, followed by the transfer of 100 ⁇ _ of diluted murine sera, and incubated for 2h at room temperature with gentle rocking. After incubation, the plate was washed 3x with PSBT for 5 mins.
  • mice were challenged with 1 .7x10 7 ⁇ 8.6x10 6 CFU (0.5 mL) of S. pneumonia (serotype 4, TIGR4) injected IP under isoflurane anesthesia. This dose is ca. 30-fold greater than the calculated LD50.
  • FIG. 23 shows the survival curves for the mice. Concentration of bacteria prior to administration as well as post-administration was quantified based on CFU observed on THY plates. Mice were monitored daily or more as needed. Moribund mice were humanely euthanized.
  • the same cells utilized for western blot were instead incubated for 1 h with 2mg/mL BSA in PBS for blocking.
  • the cells were subsequently incubated with ant-biotin antibody at a dilution of 1 /1000 for 1 h in PBST.
  • Cells were washed with PBST 3 times for 5 mins each, and

Abstract

L'invention concerne des conjugués immunogènes cellule entière – protéine contenant une protéine porteuse et une cellule entière dont la surface externe comprend un antigène polyol qui est lié à la protéine porteuse par l'intermédiaire d'un lieur. Le lieur peut être covalent, ou le lieur peut comprendre une paire d'affinité. Le lieur covalent peut être de formule : Z1-C(Z3)-N(H)-N(H)-(-C(O)-(L-C(O))n-N(H)-N(H)-)m-Z2, où Z1 est une liaison à un atome d'oxygène de l'antigène polyol, Z2 est une liaison à un groupe carbonyle de la protéine porteuse, Z3 est O ou NH, n et m sont chacun 0 ou 1, et L, lorsqu'il est présent, est un alkanediyl en C2-6 ou un arènediyl en C6-10. L'invention concerne également des conjugués immunogènes cellule entière – protéine contenant une protéine porteuse et une cellule entière contenant une protéine porteuse et une cellule entière dont la surface externe comprend un antigène polyol qui est lié de façon covalente à la protéine porteuse par l'intermédiaire d'un lieur formé par une réaction entre un groupe cyanate lié à l'antigène polyol et une protéine porteuse activée par hydrazine. L'invention concerne en outre des compositions pharmaceutiques contenant les conjugués immunogènes cellule entière – protéine, des procédés de préparation de conjugués immunogènes cellule entière – protéine, des procédés de préparation de conjugués antigène – protéine de polyol par l'intermédiaire de conjugués cellule entière – protéine, et des méthodes d'induction d'une réponse immunitaire chez le patient à l'aide des compositions pharmaceutiques de l'invention.
PCT/US2017/041258 2016-07-08 2017-07-07 Conjugués cellules entières – protéines, et procédés de fabrication de ces derniers WO2018009906A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662360151P 2016-07-08 2016-07-08
US62/360,151 2016-07-08

Publications (1)

Publication Number Publication Date
WO2018009906A1 true WO2018009906A1 (fr) 2018-01-11

Family

ID=60912320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/041258 WO2018009906A1 (fr) 2016-07-08 2017-07-07 Conjugués cellules entières – protéines, et procédés de fabrication de ces derniers

Country Status (1)

Country Link
WO (1) WO2018009906A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116828B2 (en) 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2023024676A1 (fr) * 2021-08-23 2023-03-02 Versitech Limited Développement de vaccins antibactériens à base d'acide pseudaminique synthétique contre acinetobacter baumannii
US11642406B2 (en) 2018-12-19 2023-05-09 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090240030A1 (en) * 2002-12-13 2009-09-24 The Trustees Of Columbia University In The City Of New York Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry
US20110212466A1 (en) * 2009-08-20 2011-09-01 Sophie Deshayes Thiol-Modified Surface Immobilization Article And Method
US20120195922A1 (en) * 2006-03-17 2012-08-02 Of Health And Human Services Methods for preparing complex multivalent immunogenic conjugates
US20140275482A1 (en) * 2013-03-14 2014-09-18 Andrei POLUKHTIN Novel benzophenone-based chromophoric crosslinkers and reagents for incorporation of biotin or other haptens into macromolecules
US20160136257A1 (en) * 2006-08-07 2016-05-19 President And Fellows Of Harvard College Protein matrix vaccines and related methods of making and administering such vaccines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090240030A1 (en) * 2002-12-13 2009-09-24 The Trustees Of Columbia University In The City Of New York Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry
US20120195922A1 (en) * 2006-03-17 2012-08-02 Of Health And Human Services Methods for preparing complex multivalent immunogenic conjugates
US20160136257A1 (en) * 2006-08-07 2016-05-19 President And Fellows Of Harvard College Protein matrix vaccines and related methods of making and administering such vaccines
US20110212466A1 (en) * 2009-08-20 2011-09-01 Sophie Deshayes Thiol-Modified Surface Immobilization Article And Method
US20140275482A1 (en) * 2013-03-14 2014-09-18 Andrei POLUKHTIN Novel benzophenone-based chromophoric crosslinkers and reagents for incorporation of biotin or other haptens into macromolecules

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARSLAN ET AL.: "Cyclodextrin Mediated Polymer Coupling via Thiol-Maleimide Conjugation: Facile Access to Functionalizable Hydrogels", RSC ADVANCES, vol. 4, 28 October 2014 (2014-10-28), pages 1 - 9, XP055450691 *
PASSWELL ET AL.: "Safety and Immunogenicity of Improved Shigella O-Specific Polysaccharide-Protein Conjugate Vaccines in Adults in Israel", INFECT. IMMUN., vol. 69, no. 3, 30 March 2001 (2001-03-30), pages 1351 - 1357, XP002305349 *
WANG ET AL.: "Synthesis of Neisseria meningitidis Serogroup W135 Capsular Oligosaccharides for Immunogenicity Comparison and Vaccine Development", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 52, 26 August 2013 (2013-08-26), pages 9157 - 9161, XP055195115 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116828B2 (en) 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US11850278B2 (en) 2017-12-06 2023-12-26 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US11642406B2 (en) 2018-12-19 2023-05-09 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2023024676A1 (fr) * 2021-08-23 2023-03-02 Versitech Limited Développement de vaccins antibactériens à base d'acide pseudaminique synthétique contre acinetobacter baumannii

Similar Documents

Publication Publication Date Title
US9533032B2 (en) Protein matrix vaccines and related methods of making and administering such vaccines
EP2519265B1 (fr) Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
RU2634405C2 (ru) Иммуногенная композиция
KR20130098362A (ko) 면역원성 조성물
KR101670340B1 (ko) 폴리양이온을 포함하는 단백질 매트릭스 백신 조성물
US20120231086A1 (en) Protein matrix vaccines of improved immunogenicity
JP2019123720A (ja) 治療において使用するための免疫原性組成物
WO2018009906A1 (fr) Conjugués cellules entières – protéines, et procédés de fabrication de ces derniers
WO2017011338A1 (fr) Couplage à médiation par la sortase de conjugués protéine-polysaccharide immunogène et leur utilisation
BE1024282B1 (fr) Compositions immunogènes
Wu et al. Investigation of nontypeable Haemophilus influenzae outer membrane protein P6 as a new carrier for lipooligosaccharide conjugate vaccines
US20030068324A1 (en) Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid
Edwards et al. Vaccines against group B Streptococcus
JP2024041903A (ja) 複合糖質ワクチン

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17825054

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17825054

Country of ref document: EP

Kind code of ref document: A1